Disease Medical Schools Molecular Biology 
Broad Institute
JANUARY 30, 2024
Bhattacharyya wears many coats today, splitting his time between the Broad and the infectious disease ward at MGH, where a diagnostic method he developed at Broad is now being tested to see if it helps patients quickly receive the best antibiotics for their infections. A combined MD/PhD program offered both opportunities.
Broad Institute
JUNE 21, 2023
With further development, the findings could inform a potential treatment that lowers oxygen levels in certain tissues in humans to reverse advanced disease. The study appeared recently in Human Molecular Genetics. “If Mootha’s lab has been studying hypoxia as a potential treatment for rare neurological diseases since 2016.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
NOVEMBER 8, 2023
Cell therapies hold immense promise for revolutionising the treatment of some of the most challenging diseases, but several technological and logistical hurdles stand in the way of unlocking their full potential. By harnessing the fundamental biology of T cells, Senza5 can be used to improve the efficacy of almost any CAR-T therapy.
Broad Institute
APRIL 25, 2024
He started to imagine how the deadly and contagious disease, if confirmed, might spread to half the city’s population. Eight of the 20 patients died, but the spread of the disease in Nigeria stopped there. Ozonoff is also an associate professor of pediatrics at Harvard Medical School and a scientist at Boston Children’s Hospital.
Broad Institute
AUGUST 7, 2023
Now, a team of MIT, Massachusetts General Hospital (MGH), Broad Institute of MIT and Harvard, and Harvard Medical School (HMS) researchers has discovered how STING activates those two pathways. Food and Drug Administration has not approved any STING agonist thus far, although multiple clinical trials are currently underway.
Drug Target Review
JULY 1, 2024
As a non-NSAID, it reduces adverse effects associated with these pain relief drugs, including kidney injury, GI gastritis/ulceration and blood pressure elevation, which can affect patients with cardiovascular disease and the elderly. We set out to improve health by developing a novel non-opioid that avoids potential abuse.
Drug Target Review
AUGUST 29, 2024
MR : We started by focusing on T-cell lymphoma because it is an orphan disease with very limited effective therapies, but, importantly, we think that CD5 deletion enhances any type of CAR T cell treatment. How might the CD5 knockout approach impact the treatment of other types of cancers beyond T-cell lymphoma?
Expert insights. Personalized for you.
137 
Let's personalize your content